Robert C Smith1,2, Lawrence Maayan3, Renrong Wu4, Mary Youssef5, Zhihui Jing4, Henry Sershen6,7, Victoria Szabo6, Jordan Meyers8, Hua Jin9, Jinping Zhao4, John M Davis10. 1. Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA. Robert.Smith@nki.rfmh.org. 2. Department of Psychiatry, NYU Langone Medical Center, New York, NY, USA. Robert.Smith@nki.rfmh.org. 3. Albany Medical College, Albany, NY, USA. 4. Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, and Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. 5. Harlem Hospital, Columbia University, New York, NY, USA. 6. Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA. 7. Department of Psychiatry, NYU Langone Medical Center, New York, NY, USA. 8. Oregon Health and Science University, Portland, OR, USA. 9. University of California San Diego, Department of Psychiatry, San Diego, and VA San Diego Healthcare System, San Diego, CA, USA. 10. Psychiatric Institute University of Illinois, Chicago, Illinois and John Hopkins University Medical School, Baltimore, USA.
Abstract
RATIONALE: Weight gain during treatment with antipsychotics is a prominent side-effect, especially with some second-generation antipsychotics, such as olanzapine and clozapine, and pharmacological treatments which ameliorate this side-effect are important to investigate. Decreases in histaminergic transmission in the brain induced by antipsychotics may be one of the mechanisms contributing to weight gain. Since betahistine is a histaminergic agonist, it may potentially counteract the weight gain effects of antipsychotics. METHOD: We conducted a double-blind placebo-controlled study to evaluate the effects of 12 weeks of treatment with betahistine (N = 29) or placebo (N = 22) in adolescents and adults on anthropomorphically measured weight-related parameters, appetite, and fasting glucose-lipid and leptin levels in 51 patients treated with first and/or second-generation antipsychotics who had gained weight during treatment or had high body-mass-index (BMI). Psychopathology and side-effects were also assessed with relevant scales. RESULTS: In a sub-group of patients being treated with olanzapine or clozapine (n = 26), betahistine was significantly (P < .05) better than placebo in preventing increases in weight (3.1 kg less weight gain than placebo), BMI, and waist circumference. Betahistine did not decrease weight or BMI in patients treated with other antipsychotics. There was also no effect of betahistine on preventing weight or BMI gain in the total combined sample of all subjects. Betahistine did not significantly improve appetite or glucose-lipid measures in either subgroup. There were no significant differences in side-effects or psychopathology changes in the betahistine- vs. placebo-treated patients. CONCLUSIONS: These results suggest that betahistine may potentially be a useful adjunctive drug for decreasing weight gain in patients treated with antipsychotics that are potent histamine antagonists, such as olanzapine or clozapine, but may not be useful for this purpose in patients on other antipsychotic medications. The results justify larger placebo-controlled studies to further confirm these effects before specific recommendations can be made for routine use.
RCT Entities:
RATIONALE: Weight gain during treatment with antipsychotics is a prominent side-effect, especially with some second-generation antipsychotics, such as olanzapine and clozapine, and pharmacological treatments which ameliorate this side-effect are important to investigate. Decreases in histaminergic transmission in the brain induced by antipsychotics may be one of the mechanisms contributing to weight gain. Since betahistine is a histaminergic agonist, it may potentially counteract the weight gain effects of antipsychotics. METHOD: We conducted a double-blind placebo-controlled study to evaluate the effects of 12 weeks of treatment with betahistine (N = 29) or placebo (N = 22) in adolescents and adults on anthropomorphically measured weight-related parameters, appetite, and fasting glucose-lipid and leptin levels in 51 patients treated with first and/or second-generation antipsychotics who had gained weight during treatment or had high body-mass-index (BMI). Psychopathology and side-effects were also assessed with relevant scales. RESULTS: In a sub-group of patients being treated with olanzapine or clozapine (n = 26), betahistine was significantly (P < .05) better than placebo in preventing increases in weight (3.1 kg less weight gain than placebo), BMI, and waist circumference. Betahistine did not decrease weight or BMI in patients treated with other antipsychotics. There was also no effect of betahistine on preventing weight or BMI gain in the total combined sample of all subjects. Betahistine did not significantly improve appetite or glucose-lipid measures in either subgroup. There were no significant differences in side-effects or psychopathology changes in the betahistine- vs. placebo-treated patients. CONCLUSIONS: These results suggest that betahistine may potentially be a useful adjunctive drug for decreasing weight gain in patients treated with antipsychotics that are potent histamine antagonists, such as olanzapine or clozapine, but may not be useful for this purpose in patients on other antipsychotic medications. The results justify larger placebo-controlled studies to further confirm these effects before specific recommendations can be made for routine use.
Authors: Robert C Smith; Jean-Pierre Lindenmayer; Qiaoyan Hu; Erin Kelly; Thomas F Viviano; James Cornwell; Sumathi Vaidhyanathaswamy; Santica Marcovina; John M Davis Journal: Schizophr Res Date: 2010-05-10 Impact factor: 4.939
Authors: Elaine Weiner; Robert R Conley; M Patricia Ball; Stephanie Feldman; James M Gold; Deanna L Kelly; Ikwunga Wonodi; Robert P McMahon; Robert W Buchanan Journal: Neuropsychopharmacology Date: 2010-07-21 Impact factor: 7.853
Authors: Robert C Smith; Jean-Pierre Lindenmayer; John M Davis; Erin Kelly; Thomas F Viviano; James Cornwell; Qiaoyan Hu; Anzalee Khan; Sumathi Vaidhyanathaswamy Journal: J Clin Psychiatry Date: 2009-10-06 Impact factor: 4.384
Authors: Sri Mahavir Agarwal; Nicolette Stogios; Zohra A Ahsan; Jonathan T Lockwood; Markus J Duncan; Hiroyoshi Takeuchi; Tony Cohn; Valerie H Taylor; Gary Remington; Guy E J Faulkner; Margaret Hahn Journal: Cochrane Database Syst Rev Date: 2022-10-03
Authors: Leslie Citrome; Joseph P McEvoy; Mark S Todtenkopf; David McDonnell; Peter J Weiden Journal: Neuropsychiatr Dis Treat Date: 2019-09-05 Impact factor: 2.570